MARKET

SEPN

SEPN

Septerna, Inc.
NASDAQ
27.88
+0.10
+0.36%
After Hours: 27.88 0 0.00% 17:19 12/31 EST
OPEN
27.62
PREV CLOSE
27.78
HIGH
28.32
LOW
27.50
VOLUME
168.88K
TURNOVER
--
52 WEEK HIGH
30.50
52 WEEK LOW
4.170
MARKET CAP
1.25B
P/E (TTM)
-18.5016
1D
5D
1M
3M
1Y
5Y
1D
My Market Outlook For 2026: Focus On Pharma For Consistent Returns, Potential Skyrocketing Shares
Seeking Alpha · 12/29/2025 16:00
Weekly Report: what happened at SEPN last week (1222-1226)?
Weekly Report · 12/29/2025 09:44
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Benzinga · 12/23/2025 14:47
Coty downgraded, Spruce Biosciences initiated: Wall Street’s top analyst calls
TipRanks · 12/23/2025 14:35
Septerna Price Target Announced at $43.00/Share by Jones Trading
Dow Jones · 12/23/2025 14:19
Septerna Initiated at Buy by Jones Trading
Dow Jones · 12/23/2025 14:19
Jones Trading Initiates Coverage On Septerna with Buy Rating, Announces Price Target of $43
Benzinga · 12/23/2025 14:09
SEPTERNA INC <SEPN.O>: JONESTRADING INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $43
Reuters · 12/23/2025 12:35
More
About SEPN
Septerna, Inc. is a clinical-stage biotechnology company. The Company is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. It is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with unmet needs. It is focused on therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.

Webull offers Septerna, Inc. stock information, including NASDAQ: SEPN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SEPN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SEPN stock methods without spending real money on the virtual paper trading platform.